Solara Pharma board approves new CFO, revises executive pay

Solara Active Pharma Sciences Limited announced that its board of directors, at a meeting held on November 05, 2025, approved several key items. These included the appointment of Sarat Kumar Asuri as the chief financial officer and chief investor relations officer (CIRO) of the company.

The board also sanctioned revisions to the remuneration of Mohan Muthunarayanan, the whole-time director, in line with the company's remuneration policy and within previously approved shareholder limits. Additionally, remuneration for eligible senior management personnel will be revised.

Furthermore, the existing risk management policy of Solara Active Pharma Sciences Limited was reviewed and confirmed by the board during the meeting. These approvals are disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.